Kidney Disease
Risk for interferon-related kidney failure warrants close patient management
Published in Hepatitis Weekly, November 17th, 2003
According to a study from Saudi Arabia, "hepatitis C virus (HCV) infection is the most common cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma worldwide. Recombinant interferon alpha (IFN-alpha) is currently the recommended therapy for patients with HCV-induced chronic liver disease. A flu-like syndrome and depression are the most common side effects of IFN-alpha therapy."
"Severe renal adverse effects-including nephrotic syndrome and acute renal failure-are, fortunately, rare, but may be life-threatening; these are often reversible following prompt...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-11-17)
More Articles from Hepatitis Weekly
- Cardiology
Hepatitis C virus may play a role in hypertrophic cardiomyopathy formation - Transplantation
Undetected tumors won't change cancer-related liver transplant outcomes - Blood Products
Hemophilia patients in Japan bear a novel subtype of GB virus C hepatitis G - Immunology
HBV gene changes precipitate viral breakthrough after liver transplantation - Liver Cancer
Viral hepatitis related cancers prevail because of persistent inflammation - Cancer Treatment
FDA grants Fast Track Designation for HCC treatment - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
